Phytosphingosine Salicyloyl + Pramoxine Hydrochloride

Verify with FDA CVM →

20 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
20
Total Reports
1
Deaths Reported
500.0%
Death Rate

Active Ingredients

Phytosphingosine SalicyloylPramoxine Hydrochloride

Administration Routes

TopicalOphthalmic

Species Affected

Dog 16
Human 3
Cat 1

Most Affected Breeds

Unknown 3
Retriever - Golden 3
Retriever - Labrador 2
Dachshund (unspecified) 1
Maltese 1
Spaniel - Cocker American 1
Domestic Shorthair 1
Shepherd Dog - German 1
Brittany 1
Dog (unknown) 1

Most Reported Reactions

Pruritus 4
Erythema (for urticaria see Immune SOC) 3
Glaucoma 3
Hives (see also 'Skin') 2
Application site erythema 2
Application site pruritus 2
Lack of efficacy - NOS 2
Urticaria 2
Accidental exposure 1
Red eye 1
Eye irritation 1
Application site reddening 1

Outcome Breakdown

Recovered/Normal
9 (45.0%)
Ongoing
6 (30.0%)
Outcome Unknown
4 (20.0%)
Euthanized
1 (5.0%)

Data Summary

Metric Value
Total adverse event reports 20
Reports involving death 1
Case-fatality rate (reported events) 500.0%
Distinct species in reports 3
Distinct breeds in reports 15
Distinct reactions reported 20
Active ingredients on file 2

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Phytosphingosine Salicyloyl + Pramoxine Hydrochloride Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 20 adverse event reports referencing Phytosphingosine Salicyloyl + Pramoxine Hydrochloride, including 1 reports in which the animal died — a 500.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Phytosphingosine Salicyloyl, Pramoxine Hydrochloride. Reported administration routes include Topical, Ophthalmic. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Phytosphingosine Salicyloyl + Pramoxine Hydrochloride reports are Dog (16 reports), Human (3 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Unknown (3), Retriever - Golden (3), Retriever - Labrador (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Phytosphingosine Salicyloyl + Pramoxine Hydrochloride are Pruritus (4), Erythema (for urticaria see Immune SOC) (3), Glaucoma (3), Hives (see also 'Skin') (2). Of the 20 reports with a coded outcome, Recovered/Normal is the leading category at 45.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Phytosphingosine Salicyloyl + Pramoxine Hydrochloride.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial